Notice of Annual General Meeting of Shareholders (AGM) to be held on June 30, 2022

Notices

Akari TX / June 6, 2022

NOTICE OF GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 30, 2022 PROXY FORM (CLICK TO VIEW AND DOWNLOAD) ANNUAL REPORT AND CONSOLIDATED FINANCIAL …

Akari TX / August 17, 2018

Notice of Annual Shareholders Meeting 2018 Proxy Form Dear Shareholders of Akari Therapeutics, Plc: You are cordially invited to attend (and …

In severe or life-threatening conditions where there are no available treatment options, regulators may grant permission to provide a treating physician access to an unapproved drug; this is known as expanded access. At this time, the safety and effectiveness of nomacopan to treat diseases such as Atopic Keratoconjunctivitis (AKC), Bullous Pemphigoid (BP); Thrombotic Microangiopathy (TMA), and Paroxysmal Nocturnal Hemoglobinuria (PNH) has not been established. Until more data are available, Akari Therapeutics is not considering requests for expanded access outside of clinical trials. This policy may change as safety and efficacy are better demonstrated. For questions regarding our current expanded access policy, please contact Akari Therapeutics at +44 (0)20-8004-0261.

LONDON

NEW YORK

REGISTERED ADDRESS

EXPANDED ACCESS POLICY